PRMT5 and lymphoma: In our screen, a large fraction of lymphoma, breast and multiple myeloma cell lines exhibited close to complete growth inhibition or a net cell death phenotype, suggesting that these tumour types are the most vulnerable to the attenuation of PRMT5 activity in vitro.